quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine
Phase 3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Human Papilloma Virus
Conditions
Human Papilloma Virus
Trial Timeline
Feb 1, 2015 → Dec 1, 2015
NCT ID
NCT02382900About quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine
quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine is a phase 3 stage product being developed by Merck for Human Papilloma Virus. The current trial status is unknown. This product is registered under clinical trial identifier NCT02382900. Target conditions include Human Papilloma Virus.
What happened to similar drugs?
14 of 20 similar drugs in Human Papilloma Virus were approved
Approved (14) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02382900 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Human Papilloma Virus